ASH 59th Annual Meeting and Exposition

12/07/17

From December 9-12, the American Society of Hematology will be hosting its Annual Meeting and Exposition in Atlanta, Georgia. The meeting will provide an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field. Journal of Clinical Pathways will be covering the most relevant abstracts leading up to the meeting, as well as many of the live sessions during the meeting.


Earlier access to palliative care may increase the likelihood that patients with hematologic malignancies nearing end-of-life can die at home.

Read More

 

 

 
The relationship between transfusion dependency and health-related quality of life in patients with myelodysplastic syndromes may differ based on disease risk at diagnosis.
 
 
 
 

 

 

More than one-fifth of patients undergoing hematopoietic cell transplantation reported a lack of awareness of financial burden prior to the procedure.

Read More

 

 

 

 

A single-agent therapy conferred a favorable safety profile and exhibited evidence of durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma.

Read More

 

 

 

 

Hospice use among multiple myeloma patients at the end of life has steadily increased over time.

Read More

 

 

 

 

AML

Prognostic, Treatment Perceptions Differ Between AML Patients, Oncologists

Prognosis and cure perceptions among older adults with acute myeloid leukemia often diverge from oncologist estimates.

Read More

 

 

 

 

all

Palliative Care Use Remains Low Among Patients With Hematologic Malignancies

Palliative care utilization among patients with hematologic malignancies remains extremely low.

Read More

 

 

 

 

Patients with acute leukemia exhibited a high rate of venous thromboembolism, along with high recurrence rates.

Read More

 

 

 

 

 
Patients treated with dasatinib for newly diagnosed chronic myeloid leukemia experienced greater health care resource utilization and associated costs due to infection than patients treated with nilotinib.
 

 

 

 

Patients with sickle cell disease who are insured through Medicaid used hematology care services at a far lower rate than commercially insured patients.

Read More

 

 

 

 
Elderly patients with acute myeloid leukemia faced high health care costs in their first year following diagnosis.
 

 

 

 

 
Second malignant neoplasms have increased among younger patients with multiple myeloma.
 
 
 
 
 
Insurance status heavily influenced treatment and survival outcomes among patients with Burkitt lymphoma, but not patients with plasmablastic lymphoma.